Terapia génica en la insuficiencia cardiaca / Gene therapy for heart failure
Arch. cardiol. Méx
; 79(2): 147-156, abr.-jun. 2009. tab
Article
em Es
| LILACS
| ID: lil-565717
Biblioteca responsável:
BR1.1
ABSTRACT
Gene therapy as a therapeutic strategy for Heart Failure, is an area that within the last 10 years has experienced an important increase in research, becoming one of the most promising areas to obtain a successful therapy for heart failure due to the possibility of correcting the basic defects observed at the cellular level in this pathology. One of the first things to consider on the use of this therapy is the way to deliver the genetic material, Adenovirus, and Adeno-associated virus, have shown the best capabilities in the myocardium; the delivery by local means has shown best results when compared with peripheral administration. Multiple physiopathological mechanisms susceptible of modifying by gene therapy have been identified, including the regulation of Ca2+ fluxes during excitation-contraction coupling, altered intracellular signalling, and adrenergic system, blockade of apoptosis and angiogenesis. The objective of this review, is to made a recount about the status of the literature and analyze future perspectives for gene therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Terapia Genética
/
Insuficiência Cardíaca
Tipo de estudo:
Systematic_reviews
Limite:
Humans
Idioma:
Es
Ano de publicação:
2009
Tipo de documento:
Article